Decoy Therapeutics Joins Webull Corporate Connect Service Platform
MWN-AI** Summary
Decoy Therapeutics, Inc. (Nasdaq: DCOY), a preclinical-stage biotechnology company, has recently announced its participation in the Webull Corporate Connect Service (CCS) platform, aimed at improving communication with shareholders and investors. The move is a strategic effort to enhance transparency regarding the company’s progress in developing peptide conjugate therapeutics, particularly for unmet medical needs in areas such as respiratory viruses and gastrointestinal cancers.
Rick Pierce, the CEO of Decoy Therapeutics, emphasized the company's commitment to transparent communication, stating that engaging with the investor community is vital as they advance their strategic initiatives. Through the Webull CCS, Decoy plans to share important updates, including company news, earnings reports, and product developments, creating an additional channel for interaction with their growing shareholder base.
Webull is a leading digital investment platform that offers retail investors access to global financial markets. With over 24 million registered users, it facilitates trading in various financial instruments such as stocks, ETFs, and digital assets. Current Webull users can easily follow Decoy Therapeutics and stay updated on the latest company developments through the Webull app.
Decoy Therapeutics is leveraging advanced machine learning and AI technologies to expedite the design and manufacturing of their drug candidates. The company has garnered financial support from institutional investors and non-dilutive sources, including significant backing from the Massachusetts Life Sciences Seed Fund and participation in notable programs such as Google AI’s startup initiative.
This initiative highlights Decoy’s strategic approach towards investor relations and demonstrates their dedication to fostering a transparent and proactive relationship with their stakeholders as they continue to develop innovative therapeutic solutions in the biopharmaceutical space.
MWN-AI** Analysis
Decoy Therapeutics, Inc. (Nasdaq: DCOY) has recently joined the Webull Corporate Connect Service platform. This strategic move enhances the company’s communication capabilities with its shareholders and provides a vital avenue for the dissemination of corporate updates, earnings reports, and product developments. As a preclinical-stage biopharmaceutical firm focused on developing innovative peptide conjugate therapeutics, Decoy’s commitment to transparency is crucial as it aims to engage with its growing investor base effectively.
From a market perspective, Decoy’s entry into the Webull platform represents an opportunity for investors to stay informed on the company's strategic initiatives and progress with its drug development pipeline, particularly in addressing respiratory viruses and gastrointestinal cancers. This move could potentially attract more retail investors, as the user-friendly Webull platform offers 24/7 access to global financial markets and aligns with the evolving dynamics of investor engagement and accessibility.
However, while the partnership with Webull strengthens Decoy’s investor relations, potential investors should remain cautious. The company operates at a preclinical stage, which typically carries inherent risks associated with drug development, including regulatory hurdles and financing requirements. Investors should analyze Decoy's forward-looking statements critically, keeping in mind the uncertainties related to product development and market entry.
As Decoy Therapeutics advances its programs and initiatives, monitoring industry developments and regulatory announcements will be essential. For interested investors, paying attention to the company’s updates on the Webull platform will be crucial to making informed investment decisions. Overall, while the short-term outlook hinges on effective communication and transparency, long-term value will ultimately depend on the successful execution of its therapeutic development strategy.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- Connect with the Company on Webull here
CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it is now participating on the Webull Corporate Connect Service (CCS) platform.
Decoy's portal on the Webull CCS aims to provide an additional line of communication for shareholders and interested investors and enhance transparency with its growing shareholder base. Through Webull, the Company will release notifications regarding corporate content, such as company news, earnings reports, product news, presentations and more.
"At Decoy Therapeutics, we are committed to clear and transparent communication with our shareholders. As we advance our programs and strategic initiatives, expanding awareness and engagement with the investor community is a critical part of our approach. Joining Webull Corporate Connect complements our existing investor relations efforts and social channels, providing an additional platform to share timely company updates and connect directly with our investors," commented Rick Pierce, Chief Executive Officer of Decoy Therapeutics.
To stay up to date on Decoy's recent developments on the Webull Corporate Connect Services Platform, current Webull users can follow DCOY from the app on their smartphone or table device. To download the app and register for your free Webull account, visit www.webull.com/trading-platforms.
Others can access the Company's information on Webull here.
About Webull Financial
Webull Corporation owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 14 markets across North America, Asia Pacific, Europe, and Latin America. Webull serves more than 24 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, fractional shares, and digital assets through Webull's trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more at https://www.webullcorp.com/
About Decoy Therapeutics, Inc.
Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company's initial pipeline is focused on respiratory viruses and GI cancers. Decoy has attracted financing from institutional investors as well as significant non-dilutive capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program and the NVIDIA Inception program among other sources. The company has also received QuickFire Challenge award funding provided by the Biomedical Advanced Research and Development Authority (BARDA) through BLUE KNIGHT™, a collaboration between Johnson & Johnson Innovation – JLABS and BARDA within the Administration for Strategic Preparedness and Response.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "can," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP3ACT™ platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Current Report on Form 8-K filed on August 22, 2025, its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy's actual results may vary materially from those expected or projected.
SOURCE Decoy Therapeutics, Inc
FAQ**
How will Decoy Therapeutics Inc Com Par $0.0001 (New) DCOY utilize the Webull Corporate Connect Service to enhance shareholder communication and transparency regarding its preclinical developments?
What specific types of corporate content does Decoy Therapeutics Inc Com Par $0.0001 (New) DCOY plan to share through the Webull CCS, and how frequently can investors expect updates?
In what ways does joining the Webull Corporate Connect Service align with Decoy Therapeutics Inc Com Par $0.0001 (New) DCOY's overall strategy for engaging with the investor community and increasing awareness of its pipeline?
Can Decoy Therapeutics Inc Com Par $0.0001 (New) DCOY outline any anticipated challenges or risks associated with communicating through the Webull platform, especially in relation to its forward-looking statements and product development?
**MWN-AI FAQ is based on asking OpenAI questions about Decoy Therapeutics Inc Com Par $0.0001 (New) (NASDAQ: DCOY).
NASDAQ: DCOY
DCOY Trading
1.01% G/L:
$7.50 Last:
8,377 Volume:
$7.60 Open:
